TAK-580 + nivolumab

TAK-580 + nivolumab is an experimental combination therapy for advanced melanoma that merges a small molecule pan-RAF inhibitor (TAK-580, also known as MLN2480) with nivolumab, a monoclonal antibody programmed death-1 (PD-1) checkpoint inhibitor. TAK-580 disrupts RAF dimerization in the MAPK pathway, targeting mutated or aberrant RAS/RAF signaling, while nivolumab enhances anti-tumor immunity by blocking PD-1-mediated T-cell inhibition. Their combination aims to overcome resistance to immunotherapy in melanoma by simultaneously targeting oncogenic signaling and relieving immune suppression[1][3][5].

Brand names

Opdivo

Other names

TAK-580 + nivolumab